[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360556-105":59,"doc-detail-360556-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","computationally-derived-spatial-immune-signature-identifies-trastuzumab-responders-in-her2-breast-cancer-nsabp-b-41-clinical-trial-validation","Computationally Derived Spatial Immune Signature - Identifies Trastuzumab Responders in HER2+ Breast Cancer - NSABP B-41 Clinical Trial Validation","","Trastuzumab-based chemotherapy improves outcomes in HER2-positive breast cancer, but response varies widely. DeSTIL (Density and Spatial architecture of Tumor-Infiltrating Lymphocytes) is a computational image-derived immune signature built from hematoxylin and eosin slides, capturing immune spatial organization and tumor interactions. DeSTIL was trained on TCGA HER2+ slides and validated in NSABP B-41 (phase III) across treatment comparisons. DeSTIL-positive patients showed significantly better event-free survival with trastuzumab and a significant signature–treatment interaction. Gene-expression results further supported image-derived stratification.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/computationally-derived-spatial-immune-signature-identifies-trastuzumab-responders-in-her2-breast-cancer-nsabp-b-41-clinical-trial-validation/360556/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/computationally-derived-spatial-immune-signature-identifies-trastuzumab-responders-in-her2-breast-cancer-nsabp-b-41-clinical-trial-validation/360556.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is DeSTIL and what does it measure?","Question",{"text":112,"@type":113},"DeSTIL is a computational signature derived from hematoxylin and eosin slides. It captures the spatial organization of tumor-infiltrating lymphocytes and their interactions with nonimmune cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was DeSTIL developed and validated?",{"text":117,"@type":113},"DeSTIL was trained on HER2+ breast cancer slides from The Cancer Genome Atlas and validated using the phase III NSABP B-41 randomized clinical trial cohort, comparing trastuzumab, lapatinib, or their combination.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about trastuzumab benefit in DeSTIL-positive patients?",{"text":121,"@type":113},"In NSABP B-41, DeSTIL-positive patients had significantly improved event-free survival with trastuzumab versus the combination arm, along with a significant signature–treatment interaction. No EFS difference was observed in DeSTIL-negative patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360556,1790396447,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Computationally Derived Spatial Immune Signature  \nIdentifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation  \nSatvika Bharadwaj1, Germn Corredor1, Hilmi Al-Shakhshir2, Sebastian Medina1, Sahar N. Almahfouz3, Rohan Dhamdhere1, Tilak Pathak3, Pingfu Fu4, Yuan Liu5, Shipra Gandhi6, Sunil Badve7, and Anant Madabhushi1,2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Trastuzumab-based chemotherapy has improved outcomes in human epidermal growth factor receptor 2 (HER2)– positive breast cancer, but treatment benefit varies among patients. Predictive signatures are needed to identify patients most likely to respond to these therapies.\u003Cbr>Experimental Design: We developed Density and Spatial architecture of Tumor-Infiltrating Lymphocytes (DeSTIL), a computational signature derived from hematoxylin and eosin slides. The signature captures spatial organization of immune cells and interactions with nonimmune cells. DeSTIL was trained on HER2+ breast cancer slides from The Cancer Genome Atlas (n ¼ 250) and validated in a phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-41 randomized clinical trial (n ¼ 221), which compared chemotherapy plus trastuzumab, lapatinib, or combination. The DeSTIL scores were dichotomized into positive and negative groups, and event-free survival (EFS) was assessed using Cox proportional hazards with interaction terms.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: In NSABP B-41, DeSTIL-positive patients (n ¼ 61) showed significantly improved event-free survival (EFS) with trastuzumab compared with the combination arm [hazard ratio (HR) ¼ 0.09; 95% confidence interval (CI) ¼ 0.01–0.77; P ¼ 0.006] and a significant signature–treatment interaction (P ¼ 0.024) . No EFS difference was observed in DeSTIL-negative patients (n ¼ 160) . Gene expression analysis supported the image-derived signature stratifying DeSTIL-positive and DeSTILnegative tumors. In an exploratory pathologic complete response analysis, a classifier trained on University Hospitals Cleveland slides achieved AUCs of 0.70 in the training cohort and 0.63 in the trastuzumab arm of the NSABP B-41 validation cohort.\u003Cbr>Conclusions: DeSTIL identifies a subset of HER2+ patients who derive greater benefit from trastuzumab. These findings support the potential of computationally derived immune architecture to inform selection of standard HER2-targeted therapies. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nHuman epidermal growth factor receptor 2 (HER2)–positive breast cancers account for 15% to 20% of new breast cancer diagnoses (1) . Before the development of HER2-targeted therapies, these tumors carried a high risk of recurrence and poor survival (2) . The development of trastuzumab, pertuzumab, and other HER2-targeting therapies transformed therapy for early HER2+ breast cancer, by improving the 5-year ","cbCaijCKVmL2xQAv","https://ap.wps.com/l/cbCaijCKVmL2xQAv","pdf",15240639,11,"English","# Purpose\n# Experimental Design\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What is DeSTIL and what does it measure?\",\"answer\":\"DeSTIL is a computational signature derived from hematoxylin and eosin slides. It captures the spatial organization of tumor-infiltrating lymphocytes and their interactions with nonimmune cells.\"},{\"question\":\"How was DeSTIL developed and validated?\",\"answer\":\"DeSTIL was trained on HER2+ breast cancer slides from The Cancer Genome Atlas and validated using the phase III NSABP B-41 randomized clinical trial cohort, comparing trastuzumab, lapatinib, or their combination.\"},{\"question\":\"What did the study find about trastuzumab benefit in DeSTIL-positive patients?\",\"answer\":\"In NSABP B-41, DeSTIL-positive patients had significantly improved event-free survival with trastuzumab versus the combination arm, along with a significant signature–treatment interaction. No EFS difference was observed in DeSTIL-negative patients.\"}]","Computationally Derived Spatial Immune Signature - Identifies Trastuzumab Responders in HER2+ Breast Cancer - NSABP B-41 Clinical Trial Validation | PDF",1790140508,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22887e040758dcfbfa367916724abbc1.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1975f70d45e1e75e77affb726ec52c8a.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a5defd5b72ce87598e8d486f22991bf.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eddf7028fe9ab9d18cd354a694cda11c.webp",980,1311]